The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
114241093 11424109 3 F 20110708 20160914 20150827 20160922 EXP JP-ASTRAZENECA-2013SE87674 ASTRAZENECA YASUDA T, ET AL.. CASE OF GEFITINIB-INDUCED LUNG DISORDER 18 MONTHS AFTER THE START OF THE DRUG. THE 112ND ANNUAL MEETING OF THE JAPANESE SOCIETY FOR TUBERCULOSIS KINKI BRANCH 2013; 78-. 26970.00 DY F Y 52.00000 KG 20160922 MD JP JP

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
114241093 11424109 1 PS IRESSA GEFITINIB 1 Oral 114500 MG D 0 250 MG TABLET QD
114241093 11424109 2 SS IRESSA GEFITINIB 1 Oral 114500 MG D 0 250 MG TABLET QOD
114241093 11424109 3 SS IRESSA GEFITINIB 1 Oral 114500 MG D 0 250 MG TABLET QD
114241093 11424109 4 SS ERYTHROCIN ERYTHROMYCIN LACTOBIONATE 1 Oral 110100 MG D 0 100 MG TID
114241093 11424109 5 SS MUCODYNE CARBOCYSTEINE 1 Oral 456000 MG D 0 500 MG TID
114241093 11424109 6 SS LAC-B BIFIDOBACTERIUM SPP. 1 Oral 33 G Y 0 1 G TID
114241093 11424109 7 C DAONIL GLYBURIDE 1 Oral 0 1.25 MG TABLET QD
114241093 11424109 8 C PERDIPINE LA 2 Oral 0 40 MG CAPSULE BID
114241093 11424109 9 C HYPADIL NIPRADILOL 1 Oral 0 3 MG TABLET BID
114241093 11424109 10 C DEPAS ETIZOLAM 1 Oral 0 .5 MG TABLET QD
114241093 11424109 11 C EUGLUCON GLYBURIDE 1 0
114241093 11424109 12 C ALINAMIN F FURSULTIAMINE HYDROCHLORIDE 1 0
114241093 11424109 13 C LOXONIN LOXOPROFEN SODIUM 1 0
114241093 11424109 14 C RINLAXER CHLORPHENESIN CARBAMATE 1 0
114241093 11424109 15 C ISALON UNSPECIFIED INGREDIENT 1 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
114241093 11424109 1 Non-small cell lung cancer
114241093 11424109 2 Non-small cell lung cancer
114241093 11424109 3 Non-small cell lung cancer
114241093 11424109 4 Bronchitis chronic
114241093 11424109 5 Bronchitis chronic
114241093 11424109 6 Diarrhoea
114241093 11424109 7 Diabetes mellitus
114241093 11424109 8 Hypertension
114241093 11424109 9 Hypertension
114241093 11424109 10 Insomnia

Outcome of event

Event ID CASEID OUTC COD
114241093 11424109 DE
114241093 11424109 HO

Reactions reported

Event ID CASEID DRUG REC ACT PT
114241093 11424109 Dermatitis acneiform
114241093 11424109 Diarrhoea
114241093 11424109 Interstitial lung disease
114241093 11424109 Lung disorder
114241093 11424109 Paronychia
114241093 11424109 Rash

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
114241093 11424109 1 20110531 201201 0
114241093 11424109 2 201201 201207 0
114241093 11424109 3 201207 20121125 0
114241093 11424109 4 20111125 20121125 0
114241093 11424109 5 20120127 20121125 0
114241093 11424109 6 20121106 20121116 0